atazanavir + ritonavir + rosiglitazone

Atazanavir + ritonavir + rosiglitazone is a combination of three small molecule drugs, each with distinct mechanisms and indications. Atazanavir is an HIV-1 protease inhibitor that prevents the cleavage of viral polyproteins, resulting in immature, non-infectious HIV particles. Ritonavir acts primarily as a pharmacokinetic enhancer by inhibiting CYP3A4-mediated metabolism, thereby increasing plasma concentrations of atazanavir when co-administered; it also has direct protease inhibitor activity. Both are used together as part of antiretroviral therapy for the treatment of HIV-1 infection in adults and children[1][2][3][7]. Rosiglitazone is an oral thiazolidinedione antidiabetic agent that acts as a selective agonist for peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue, muscle, and liver; it is indicated for glycemic control in type 2 diabetes mellitus[5]. This triple combination does not represent a standard or approved regimen but may be considered experimentally or off-label where both HIV infection and type 2 diabetes coexist.

Other names

atazanavir sulfateritonavir (ABT-538)rosiglitazone maleate